| The current study characterizes the range of systemic estradiol concentrations in premenopausal women associated with relugolix combination therapy. |
| The data highlight the importance of a 1-mg dose of estradiol as a component of relugolix combination therapy in order to achieve systemic exposures to estradiol within a range that provides therapeutic effects while minimizing the frequency and severity of vasomotor symptoms and bone mineral density loss. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.